Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jun;47(6):1830-6.
doi: 10.1128/JCM.00029-09. Epub 2009 Apr 22.

Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma

Affiliations

Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma

Henry Lik-Yuen Chan et al. J Clin Microbiol. 2009 Jun.

Abstract

We aimed to investigate the impact of hepatitis B virus (HBV) DNA on the development of hepatocellular carcinoma (HCC). We conducted a case/control study based on 506 chronic HBV patients followed up since 1997. Forty-one patients developed HCC, and each of them was age and gender matched with two simultaneously recruited controls without HCC. HBV DNA was measured at the initial visit, at yearly intervals, and at the last visit. Patient age at the time of HCC development was 55 +/- 9 years. Forty-nine (40%) patients experienced antiviral treatment. The median time from diagnosis to the development of HCC was 17 months, and the control patients were followed for 92 months. At the trough level (defined as lowest level among all studied visits), more (27 patients; 66%) HCC patients had HBV DNA levels of >10,000 copies/ml than the controls (17 patients; 21%). The area under the receiver operating characteristic curve of the trough log HBV DNA level for HCC was 0.79 (95% confidence interval [CI], 0.69 to 0.89). Trough log HBV DNA (odds ratio, 11.4; 95% CI, 3.6 to 37.6; P < 0.0001) and liver cirrhosis (odds ratio, 11.4; 95% CI, 3.6 to 36.2; P < 0.0001) levels were independently associated with HCC after an adjustment for age, gender, antiviral treatment, and HBV genotype. The difference in the trough HBV DNA level was more obvious among untreated patients (5.7 +/- 1.4 log copies/ml in HCC patients versus 3.2 +/- 1.3 log copies/ml in control patients; P < 0.0001) than among those who had received antiviral treatment (3.0 +/- 1.4 log copies/ml in HCC patients versus 2.5 +/- 0.9 log copies/ml in control patients; P = 0.38). A high trough HBV DNA level was associated with a higher risk of HCC. Whether antiviral treatment could prevent HCC was uncertain.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
ROC curves of log HBV DNA at different time points for HCC. The area under the ROC curve for the first log HBV DNA (LogDNA_first) is 0.65 (95% CI, 0.50 to 0.71; P = 0.059). The area under the ROC curve for the last log HBV DNA (LogDNA_last) is 0.72 (95% CI, 0.62 to 0.81; P < 0.0001). The area under the ROC curve for the peak log HBV DNA (LogDNA_peak) is 0.51 (95% CI, 0.41 to 0.61; P = 0.88). The area under the ROC curve for the trough log HBV DNA (LogDNA_trough) is 0.79 (95% CI, 0.69 to 0.89; P < 0.0001).
FIG. 2.
FIG. 2.
ROC curves of ALT at different time points for HCC. The area under the ROC curve for the first ALT (ALT_first) is 0.59 (95% CI, 0.48 to 0.69; P = 0.13). The area under the ROC curve for the last ALT (ALT_last) is 0.67 (95% CI, 0.57 to 0.77; P = 0.002). The area under the ROC curve for the peak ALT (ALT_peak) is 0.60 (95% CI, 0.50 to 0.71; P = 0.063). The area under the ROC curve for the trough ALT (ALT_trough) is 0.66 (95% CI, 0.55 to 0.76; P = 0.005).

Similar articles

Cited by

References

    1. Chan, H. L. Y. 2002. Changing scene in hepatitis B serology interpretation. Hosp. Med. 6316-19. - PubMed
    1. Chan, H. L. Y., N. W. Y. Leung, M. Hussain, M. L. Wong, and A. S. Lok. 2000. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 31763-768. - PubMed
    1. Chan, H. L. Y., Y. Hui, N. W. Y. Leung, J. Y. L. Ching, F. K. L. Chan, and J. J. Y. Sung. 2000. Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus (HBV) infected patients. Am. J. Gastroenterol. 953547-3551. - PubMed
    1. Chan, H. L. Y., A. K. K. Chui, W. Y. Lau, F. K. L. Chan, M. L. Wong, C. H. Tse, A. R. N. Rao, J. Wong, and J. J. Y. Sung. 2002. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J. Med. Virol. 68182-187. - PubMed
    1. Chan, H. L. Y., S. W. C. Tsang, C. T. Liew, C. H. Tse, M. L. Wong, J. Y. L. Ching, N. W. Y. Leung, J. S. L. Tam, and J. J. Y. Sung. 2002. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am. J. Gastroenterol. 97406-412. - PubMed

Publication types

LinkOut - more resources